

Lucia Anna Muscarella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3289354/publications.pdf>

Version: 2024-02-01

112
papers

6,377
citations

185998

28
h-index

69108

77
g-index

113
all docs

113
docs citations

113
times ranked

10690
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Potential of Afatinib in <i>NRG1</i> -Fusion-Driven Solid Tumors: A Case Series. <i>Oncologist</i> , 2021, 26, 7-16.	1.9	31
2	Rapid EGFR evaluation from used H&E, IHC and FISH diagnostic slides with the Idylla platform. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2020-207315.	1.0	2
3	<i>NRG1</i> fusions in tumors: moving from the past to future knowledge. <i>Future Oncology</i> , 2021, 17, 487-490.	1.1	1
4	Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2021, 28, 111-134.	1.6	14
5	Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives. <i>Cancers</i> , 2021, 13, 1339.	1.7	3
6	Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis. <i>Oncotarget</i> , 2021, 12, 1470-1489.	0.8	12
7	Genomic and evolutionary classification of lung cancer in never smokers. <i>Nature Genetics</i> , 2021, 53, 1348-1359.	9.4	81
8	Clinicopathologic Features and Response to Therapy of <i>NRG1</i> -Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	0.8	32
9	<i>NRG1</i> and <i>NRG2</i> fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 865-875.	1.5	4
10	Mixed Pulmonary Adenocarcinoma and Atypical Carcinoid: A Report of Two Cases of a Non-codified Entity With Biological Profile. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 784876.	1.6	1
11	Identification of <i>EML4-ALK</i> fusion in a sporadic case of cholangiocarcinoma. <i>European Journal of Internal Medicine</i> , 2020, 71, 92-94.	1.0	6
12	Epigenetic Scanning of <i>KEAP1</i> CpG Sites Uncovers New Molecular-Driven Patterns in Lung Adeno and Squamous Cell Carcinomas. <i>Antioxidants</i> , 2020, 9, 904.	2.2	7
13	<i>NRF2</i> Regulation by Noncoding RNAs in Cancers: The Present Knowledge and the Way Forward. <i>Cancers</i> , 2020, 12, 3621.	1.7	21
14	Potential Prognostic Role of <i>SPARC</i> Methylation in Non-Small-Cell Lung Cancer. <i>Cells</i> , 2020, 9, 1523.	1.8	10
15	Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 363-372.	1.9	13
16	Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. <i>Nature Communications</i> , 2019, 10, 3407.	5.8	132
17	Methylation Density Pattern of <i>KEAP1</i> Gene in Lung Cancer Cell Lines Detected by Quantitative Methylation Specific PCR and Pyrosequencing. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2697.	1.8	15
18	Targeting <i>NRG1</i> -fusions in multiple tumour types: Afatinib as a novel potential treatment option. <i>Annals of Oncology</i> , 2019, 30, v791-v792.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Automated Workflow for Somatic and Germline Next Generation Sequencing Analysis in Routine Clinical Cancer Diagnostics. <i>Cancers</i> , 2019, 11, 1691.	1.7	5
20	Diagnostic and Prognostic Value of B4GALT1 Hypermethylation and Its Clinical Significance as a Novel Circulating Cell-Free DNA Biomarker in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1598.	1.7	35
21	Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane. <i>BMC Cancer</i> , 2019, 19, 864.	1.1	11
22	Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2531.	1.8	15
23	REDOXI-miRNA of Keap1/Nrf2 axis in lung tumors. <i>Annals of Oncology</i> , 2019, 30, ii5.	0.6	2
24	P1.14-25 Targeting NRG1-Fusions in Lung Adenocarcinoma: Afatinib as a Novel Potential Treatment Strategy. <i>Journal of Thoracic Oncology</i> , 2019, 14, S563.	0.5	2
25	P2.14-14 Comparison of Molecular Testing Modalities for Detection of NRG1 Rearrangements in Invasive Mucinous Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, S834-S835.	0.5	1
26	P2.14-32 Epigenetic Silencing of SPARC in NSCLCs. <i>Journal of Thoracic Oncology</i> , 2019, 14, S841.	0.5	0
27	NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib. <i>Annals of Oncology</i> , 2019, 30, ix23-ix24.	0.6	2
28	NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry. <i>Journal of Clinical Oncology</i> , 2019, 37, 9081-9081.	0.8	11
29	Abstract 4887: Recurrent NRG1 rearrangements in Caucasian pulmonary mucinous adenocarcinoma: results from an Italian multi-center cohort. , 2019, , .		0
30	NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry. , 2019, , .		0
31	Alterations of DNA methylation in parathyroid tumors. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 60-69.	1.6	12
32	Extraneuraxial Hemangioblastoma: Clinicopathologic Features and Review of the Literature. <i>Advances in Anatomic Pathology</i> , 2018, 25, 197-215.	2.4	24
33	Frequent <i>NRG1</i> fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. <i>Oncotarget</i> , 2018, 9, 9661-9671.	0.8	36
34	Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881559.	1.4	38
35	Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene. <i>Pathology Research and Practice</i> , 2018, 214, 1156-1165.	1.0	17
36	Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-21.	1.9	41

#	ARTICLE	IF	CITATIONS
37	Abstract 5358: Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma. , 2018, , .		1
38	Large deletion at the <i>CDC73</i> gene locus and search for predictive markers of the presence of a <i>CDC73</i> genetic lesion. <i>Oncotarget</i> , 2018, 9, 20721-20733.	0.8	12
39	Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. <i>Cell</i> , 2017, 168, 1086-1100.e10.	13.5	420
40	A malignant inflammatory myofibroblastic tumor of the hypopharynx harboring the 3a/b variants of the EML4-ALK fusion gene. <i>Oncology Letters</i> , 2017, 13, 593-598.	0.8	4
41	BRAF mutations in sarcomatoid and large cell carcinoma of the lung. <i>Human Pathology</i> , 2017, 63, 218-220.	1.1	0
42	ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e161-e163.	0.5	16
43	Pharmacokinetic drug evaluation of osimertinib for the treatment of non-small cell lung cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1281-1288.	1.5	8
44	<i>NRG1</i> : a cinderella fusion in lung cancer?. <i>Lung Cancer Management</i> , 2017, 6, 121-123.	1.5	14
45	<i>NRG1</i> -ErbB Lost in Translation: A New Paradigm for Lung Cancer?. <i>Current Medicinal Chemistry</i> , 2017, 24, 4213-4228.	1.2	19
46	Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 11187-11198.	0.8	64
47	Abstract 494: Frequent <i>NRG1</i> genomic rearrangements in invasive mucinous adenocarcinoma from caucasian patients. , 2017, , .		0
48	Abstract 2397: Epigenetic silencing in clear renal cell carcinoma: <i>KEAP1</i> promoter hypermethylation. <i>Cancer Research</i> , 2017, 77, 2397-2397.	0.4	3
49	Abstract 4441: Unveil the role of cell-free circulating microRNA in lung cancer. , 2017, , .		0
50	Keap1/Nrf2 impairing revised: are we missing the single nucleotide polymorphisms?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1752-E1754.	0.6	5
51	Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-17.	1.9	36
52	Liquid biopsy and NSCLC. <i>Lung Cancer Management</i> , 2016, 5, 91-104.	1.5	10
53	Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. <i>Scientific Reports</i> , 2016, 6, 31549.	1.6	23
54	EZH2 and ZFX oncogenes in malignant behaviour of parathyroid neoplasms. <i>Endocrine</i> , 2016, 54, 55-59.	1.1	19

#	ARTICLE	IF	CITATIONS
55	The Post-Surgical Long-Term Behaviour of Lung Carcinoid Tumours. Indian Journal of Surgery, 2015, 77, 481-485.	0.2	2
56	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	13.7	1,634
57	Abstract 3841: Effects of KEAP1 genetic and epigenetic silencing in SCLC cell lines. , 2015, , .		0
58	Abstract 3843: Nrf2-keap1 axis: uncovers molecular profile in lung carcinoids. , 2015, , .		0
59	Molecular Dissection of the VHL Gene in Solitary Capillary Hemangioblastoma of the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2014, 73, 50-58.	0.9	12
60	<i>CD74</i> NRG1 Fusions in Lung Adenocarcinoma. Cancer Discovery, 2014, 4, 415-422.	7.7	238
61	FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer, 2014, 14, 396.	1.1	10
62	Establishment and genetic characterization of ANGM-CSS, a novel, immortal cell line derived from a human glioblastoma multiforme. International Journal of Oncology, 2014, 44, 717-724.	1.4	7
63	Abstract 2251: nrf2-keap1 axis molecular profile in small cell lung cancer cell lines. , 2014, , .		0
64	A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 4140-4147.	0.8	250
65	A Genomics-Based Classification of Human Lung Tumors. Science Translational Medicine, 2013, 5, 209ra153.	5.8	365
66	Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics, 2013, 8, 105-112.	1.3	77
67	VHL Gene Alterations in Italian Patients with Isolated Renal Cell Carcinomas. International Journal of Biological Markers, 2013, 28, 208-215.	0.7	3
68	Identification and Functional Characterization of Three NoLS (Nucleolar Localisation Signals) Mutations of the CDC73 Gene. PLoS ONE, 2013, 8, e82292.	1.1	18
69	Abstract 664: Aberrant KEAP1 promoter methylation is associated with disease progression in breast cancer patients treated with epirubicin/cyclophosphamide and docetaxel chemotherapy.. , 2013, , .		0
70	Hypermethylation of the KEAP1 gene in colorectal cancer and association with disease progression.. Journal of Clinical Oncology, 2013, 31, e14655-e14655.	0.8	0
71	Alteration of Hypothalamic-Pituitary-Thyroid Axis Function in Non-Small-Cell Lung Cancer Patients. Integrative Cancer Therapies, 2012, 11, 327-336.	0.8	13
72	Hormone and Cytokine Circadian Alteration in Non-Small Cell Lung Cancer Patients. International Journal of Immunopathology and Pharmacology, 2012, 25, 691-702.	1.0	9

#	ARTICLE	IF	CITATIONS
73	602 Frequent Epigenetic Inactivation of KEAP1 Gene in Breast Cancer. <i>European Journal of Cancer</i> , 2012, 48, S143.	1.3	0
74	CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 411-422.	2.1	67
75	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	9.4	1,186
76	Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls. <i>Clinical and Experimental Medicine</i> , 2012, 12, 181-194.	1.9	19
77	Aberrant Genes Promoter Methylation in Neural Crest-Derived Tumors. <i>International Journal of Biological Markers</i> , 2012, 27, 389-394.	0.7	6
78	Circadian Aspects of Growth Hormoneâ€“Insulin-Like Growth Factor Axis Function in Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 68-74.	1.1	11
79	A rare S33C mutation of CTNNB1 encoding β -catenin in a parathyroid adenoma found in an Italian primary hyperparathyroid cohort. <i>Endocrine</i> , 2012, 41, 152-155.	1.1	17
80	Abstract 3148: Frequent epigenetic inactivation of keap1 gene in non small cell lung cancer. , 2012, , .		0
81	Neuroendocrine axes function in healthy aging: Evaluation of predictive and manipulable blood serum indexes. <i>Biomedicine and Aging Pathology</i> , 2011, 1, 16-21.	0.8	1
82	Age-related changes of GH-IGF1 axis function. <i>Biomedicine and Aging Pathology</i> , 2011, 1, 39-45.	0.8	1
83	Chronobiologic study of neuro-endocrine axis hormone sequence signalling in healthy men. <i>Biomedicine and Aging Pathology</i> , 2011, 1, 129-137.	0.8	3
84	Stage dependent destructuration of neuro-endocrine-immune system components in lung cancer patients. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 69-76.	2.5	6
85	Antiphase signalling in the neuroendocrine-immune system in healthy humans. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 275-279.	2.5	8
86	Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 435-441.	2.1	20
87	Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. <i>Endocrine</i> , 2011, 40, 481-485.	1.1	17
88	High RAD51 mRNA expression characterize estrogen receptorâ€“positive/progesteron receptorâ€“negative breast cancer and is associated with patient's outcome. <i>International Journal of Cancer</i> , 2011, 129, 536-545.	2.3	40
89	Identification of a novel RUNX2 gene mutation in an Italian family with cleidocranial dysplasia. <i>European Journal of Orthodontics</i> , 2011, 33, 498-502.	1.1	5
90	Regulation of <i>KEAP1</i> expression by promoter methylation in malignant gliomas and association with patientâ€™s outcome. <i>Epigenetics</i> , 2011, 6, 317-325.	1.3	94

#	ARTICLE	IF	CITATIONS
91	Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. <i>Epigenetics</i> , 2011, 6, 710-719.	1.3	126
92	Abstract 65: Regulation of KEAP1 expression by promoter methylation in malignant gliomas and association with patient's outcome. , 2011, , .		0
93	Candidate gene study of HOXB1 in autism spectrum disorder. <i>Molecular Autism</i> , 2010, 1, 9.	2.6	8
94	Small Deletion at the 7q21.2 Locus in a CCM Family Detected by Real-Time Quantitative PCR. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7.	3.0	10
95	Calcium-Sensing Receptor (CASR) Mutations in Hypercalcemic States: Studies from a Single Endocrine Clinic Over Three Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1819-1829.	1.8	70
96	Molecular analysis of the HuD gene in neuroendocrine lung cancers. <i>Lung Cancer</i> , 2010, 67, 69-75.	0.9	27
97	Abstract 3926: Rad51 expression is associated with estrogen and progesteron receptor status in sporadic breast cancer. , 2010, , .		0
98	VHLFrameshift Mutation as Target of Nonsense-Mediated mRNA Decay inDrosophila melanogasterand Human HEK293 Cell Line. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-9.	3.0	8
99	Molecular detection of neuron-specific ELAV-like-positive cells in the peripheral blood of patients with small-cell lung cancer. <i>Cellular Oncology</i> , 2008, 30, 291-7.	1.9	12
100	Primary Hyperparathyroidism and the Presence of Kidney Stones Are Associated with Different Haplotypes of the Calcium-Sensing Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 277-283.	1.8	83
101	HOXA1gene variants influence head growth rates in humans. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 388-390.	1.1	26
102	Novel mutations of dystrophin gene in DMD patients detected by rapid scanning in bplex exons DHPLC analysis. <i>New Biotechnology</i> , 2007, 24, 231-236.	2.7	3
103	An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocyoma. <i>Journal of Human Genetics</i> , 2007, 52, 485-491.	1.1	5
104	Identification of two novel mutations and of a novel critical region in the KRIT1 gene. <i>Neurogenetics</i> , 2007, 8, 29-37.	0.7	12
105	Diagnosis of Parathyroid Tumors in Familial Isolated Hyperparathyroidism with HRPT2 Mutation: Implications for Cancer Surveillance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2827-2832.	1.8	100
106	Hemangioblastomas of Central Nervous System: Molecular Genetic Analysis and Clinical Management. <i>Neurosurgery</i> , 2005, 56, 1215-1221.	0.6	64
107	Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in geneâ€environment interactions. <i>Molecular Psychiatry</i> , 2005, 10, 1006-1016.	4.1	115
108	Molecular Analysis of <i>NPHS2</i> and <i>ACTN4</i> Genes in a Series of 33 Italian Patients Affected by Adult-Onset Nonfamilial Focal Segmental Glomerulosclerosis. <i>Nephron Clinical Practice</i> , 2005, 99, c31-c36.	2.3	33

#	ARTICLE	IF	CITATIONS
109	Blood Ionized Calcium Is Associated with Clustered Polymorphisms in the Carboxyl-Terminal Tail of the Calcium-Sensing Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5634-5638.	1.8	115
110	Association between the HOXA1 A218G polymorphism and increased head circumference in patients with autism. <i>Biological Psychiatry</i> , 2004, 55, 413-419.	0.7	94
111	Enhanced APOE2 transmission rates in families with autistic probands. <i>Psychiatric Genetics</i> , 2004, 14, 73-82.	0.6	29
112	Menin and EZH2 activities modulate the expression of the long non-coding RNA HAR1B in parathyroid tumors. <i>Endocrine Abstracts</i> , 0, , .	0.0	1